Market Newsdesk

Recommends for the Election of the 5 Concerned Shareholder Director Nominees on the

WHITE

Consent Card

• Says Election of Tom Wetherald, Tobias Welo, Mary Pat Thompson, Andrew McCormick & Sergey Vasnetsov brings “investor-first perspective” and would represent a “superior outcome” for Taronis Fuels shareholders
• Glass Lewis Joins ISS in Recommending Significant Change at Taronis by Consenting on the WHITE Card

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Thomas Wetherald and Tobias Welo (together, the “Concerned Shareholders”, “we”, “our” or “us”), who owned more than 16.2% of the outstanding shares before the Board of Directors’ recent defensive and dilutive entrenchment maneuvers,  announced that Glass Lewis & Co. (“Glass Lewis”), a leading independent proxy advisory firm, recommends Taronis Fuels, Inc. (OTCQB: TRNF) shareholders Consent to the removal of ALL Taronis Incumbent Directors and to the Election of ALL Concerned Shareholder Nominees.

In its March 30^th report, Glass Lewis unleashed a blistering attack on the incumbent Taronis Board:

“In direct terms, the sitting board has overseen bloated cost management, implemented regressive corporate governance, ineffectually pursued critical concerns around the Company’s poorly disclosed financials and destroyed shareholder value at an alarming pace, especially given Taronis’ brief tenure on the public markets.

Glass Lewis continued:

“…items of concern cover a relatively broad spectrum, and include seemingly ineffectual investigative initiatives, poor acknowledgement of glaring operational and governance issues, and, more recently, rather maladroit gamesmanship in the run-up to the current solicitation.”

“These issues would already be a hefty millstone for a board looking to build a sturdy coalition of supportive investors. Here, however, we find the board’s footing shakier still, given four of the five targeted members are holdovers from the aforementioned Taronis Technologies, a $6.0 million non-entity now drifting along under the more anodyne moniker “BBHC, Inc.” Investors familiar with the Company’s predecessor enterprise will know that firm, operating with substantially similar oversight architecture, maintained poor governance and weak internal controls and generated tremendous destruction of shareholder value. The sitting board thus seems to lack credibility around the very volley it is seeking to deflect, further crimping an already weak case.”

Glass Lewis also was dismissive of the Taronis claims that its board is “highly qualified” and essential to Taronis “growth strategy”:

“…we identify no meaningful external sector expertise, and only limited public company experience. Indeed, the case could be made the,” highly-qualified” aspects of the collected backgrounds of Messrs. Dingess, Pollack and Staunton hinges entirely on their prior service as directors of predecessor Taronis Technologies, a firm which posted objectively poor operational metrics, maintained mediocre corporate governance and ultimately lost 99.9998% of its value during their tenures. In short, we consider there is no compelling case surrounding purported risks to institutional knowledge.”

Glass Lewis was complimentary of Wetherald and Welo’s plans for Taronis:

“…show awareness of certain transitional risks, including the need to engage with Taronis’ lenders and explore sources of capital to mitigate the prospective negative impact arising from, among other things, outsized parachute payments potentially due to the Company’s existing executive team. From there, we see the Dissidents expect the board to pursue a range of initiatives targeted at the Company’s manifold weaknesses, including completing a forensic analysis of the Company’s murky and delayed financial reporting, establishing prudent cost management targets, undertaking a profitability analysis in order to support rationalized growth of the MagneGas business and vetting international growth opportunities. The operational aspects of this plan are expected to be spearheaded by a new CEO recruited within the first several weeks, a process the Dissidents assert is already underway.”

Commenting on the Glass Lewis report, Tom Wetherald and Tobias Welo issued the following statement:

“We are pleased that Glass Lewis recognized the value destructive history of the incumbent board, and the investor-first perspective our aligned slate of nominees would bring to Taronis. As we recently stated, we are already in contact with multiple highly successful individuals in the industrial gas industry to help identify a potential replacement CEO with far more relevant and extensive experience and success in industrial gasses than either current CEO Mahoney or any member of the incumbent Board.  We are very optimistic about our ability to recruit a new CEO that can truly take Taronis Fuels to the next level.”

We strongly urge shareholders to protect the value of their investment by following Glass Lewis’s recommendation to Consent on the WHITE Card.  Shareholders should simply discard and NOT vote using any Green revocations cards they may receive from Taronis.

** permission to use Glass Lewis quotations was neither sought nor obtained.

Investors:

Saratoga Proxy Consulting LLC
(212) 257-1311
[email protected]

TAMPA, Fla., March 31, 2021 (GLOBE NEWSWIRE) — Odyssey Marine Exploration, Inc. (NASDAQ:OMEX), a deep-ocean exploration pioneer engaged in the discovery, validation and development of subsea minerals deposits in an environmentally responsible manner, reported results for the full year ended December 31, 2020, and provided an update on current projects and future plans.

“While 2020 was challenging for companies around the globe due to the COVID-19 pandemic, the Odyssey team was able to achieve, and in some cases surpass, the aggressive goals we set for ourselves,” reported Mark D. Gordon, Odyssey Chairman and CEO. “Odyssey’s business is focused on building a portfolio of subsea mineral assets that hold the potential to produce meaningful societal and economic impacts for host countries and tremendous asymmetric returns for investors.

“A key objective in 2020 was identifying and securing capital to fund the needs of the company and our subsidiaries through 2021 and into 2022. An $11M registered direct offering in August of 2020 provided operating capital to execute Odyssey’s strategic plans in 2021 and beyond and allowed Odyssey to further invest and increase our ownership interest in the subsidiary controlling the ExO deposit,” continued Gordon.

“Another key objective for 2020 was continuing to progress the NAFTA action to recover the value of our ExO Phosphate Project in Mexico. In September, we filed a strong and compelling First Memorial in the NAFTA case, which is available at https://www.odysseymarine.com/nafta. It was the culmination of many months of work by our legal team at Cooley, supported by our internal project development and research teams, to gather documentary evidence and 20 expert reports and witness statements that demonstrate the merits of the case, the strategic size and grade of the resource, the operational viability of the project, and the project’s value. We are extremely confident in our case and, with the additional litigation funding commitment from, Poplar Grove LLC, we are prepared to take the case through to its final conclusion to realize the significant value of this asset.

“Our accomplishments in 2020 have set the foundation for achievement of our 2021 strategic goals, which include further increasing the value of our expanding mineral portfolio. This encompasses not only moving current projects up the value curve including our Lihir Subsea Gold and CIC projects, but also adding new mineral projects to our portfolio.

“We recently restructured our executive team and work streams to align with our strategic goals. In order to allow John Longley, our President and COO to focus on growing and increasing the value of our mineral portfolio, we’ve asked long-time Odyssey employee and Director, Laura Barton, to take on the role of Chief Business Officer to lead strategic and business operations initiatives that support the project development goals.

“In addition, earlier this month, the Odyssey Board reinstated the seventh seat on the Board of Directors and appointed Todd Siegel to fill the seat. We’re looking forward to benefitting from Todd’s significant experience leading public companies in CEO and Director roles as we take our business to the next level of growth,” concluded Gordon.

Increasing Portfolio Value
Odyssey increases the value of its mineral portfolio in multiple ways: adding new projects through development or acquisition, gaining or increasing equity ownership in mineral projects through investment or a leveraged contracting model, and by de-risking projects through exploration and assessment and moving them up the value curve toward full operating production.

During 2020 Odyssey worked on further developing the value of two highly prospective subsea mineral projects, CIC and Lihir Subsea Gold. The company is also actively developing new projects through its proprietary Global Prospectivity Program, with the goal of identifying new, highly valuable, and societally significant subsea resources.

In 2021, we expect to receive regulatory outcomes providing permits enabling us to carry out planned exploration programs that could significantly enhance the value of one or more of our portfolio projects.  

CIC: Odyssey is a member of the CIC Consortium, which is seeking a mineral exploration license in an island nation’s Exclusive Economic Zone. The CIC Consortium was founded and is led by Odyssey co-founder and former CEO, Greg Stemm, and includes Royal Boskalis Westminster NV and Odyssey Marine Exploration.

Through a wholly owned subsidiary, Odyssey Marine Minerals, Odyssey has already earned 16 million shares (representing more than 12% of current outstanding shares of this project) through the provision of services related to resource assessment, project planning, research and project management, and Odyssey has an option to acquire an additional four million shares.

Lihir Subsea Gold: The project’s license area is adjacent to Lihir Island in Papua New Guinea where one of the world’s largest known terrestrial gold deposits is currently being mined and processed by Newcrest Mining. The license area includes at least five prospective exploration targets in two different mineralization types: seamount-related epithermal and modern placer gold. Odyssey owns approximately 80% of Bismarck Mining Corporation, Ltd, the Papua New Guinea company that holds the exploration license.

While the COVID-19 pandemic delayed plans for additional offshore exploration work in 2020, presentations to the public were made in December 2020 in compliance with and in support of the regulatory process in PNG. Upon renewal of the exploration license, we intend to conduct offshore operations work in 2021. “We are extremely excited to complete the exploration program to verify and quantify the mineralization of this potentially valuable resource and to fully understand the environmental setting in which it lies. We were on the cusp of executing this program in 2020 when the pandemic hit, making marine operations impossible to execute. The renewal will allow us to execute the same exploration program that was approved in the last license period,” said John Longley, President & COO of Odyssey.

2020 Financial Results
Consolidated financial statements as well as Odyssey’s Annual Report on Form 10-K for the period ended December 31, 2020, are available on the company’s website at www.odysseymarine.com as well as at www.sec.gov. 

About Odyssey Marine Exploration
Odyssey Marine Exploration, Inc. (Nasdaq:OMEX) is engaged in ocean exploration using innovative methods and state-of-the-art technology to provide access to critical resources worldwide. Our core focus is the discovery, validation and development of subsea mineral resources. Odyssey also provides marine services for private clients and governments. For additional details, please visit www.odysseymarine.com. 

Forward Looking Information
Odyssey Marine Exploration believes the information set forth in this Press Release may include “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission on March 31, 2021. The financial and operating projections as well as estimates of mining assets are based solely on the assumptions developed by Odyssey that it believes are reasonable based upon information available to Odyssey as of the date of this release. All projections and estimates are subject to material uncertainties and should not be viewed as a prediction or an assurance of actual future performance. The validity and accuracy of Odyssey’s projections will depend upon unpredictable future events, many of which are beyond Odyssey’s control and, accordingly, no assurance can be given that Odyssey’s assumptions will prove true or that its projected results will be achieved.

Cautionary Note to U.S. Investors
The U.S. Securities and Exchange Commission (SEC) permits mining companies, in their filings with the SEC, to disclose only those mineral deposits that a company can economically and legally extract or produce. We use certain terms in this press release, such as “measured”, “indicated,” “inferred” and “resources,” which the SEC guidelines strictly prohibit us from including in our filings with the SEC. “Inferred mineral resources” have a great amount of uncertainty as to their existence, and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an inferred mineral resource will ever be upgraded to a higher category. U.S. investors are cautioned not to assume that part or all of the inferred mineral resource exists, or is economically or legally mineable, and are urged to consider closely the disclosures in our Form 10-K which may be secured from us or from the SEC’s website at http://www.sec.gov/edgar.shtml.

CONTACT:
Laura Barton 
Odyssey Marine Exploration, Inc.
(813) 876-1776 x 2562
[email protected]

Generated positive income of $3.1M vs. a loss of $2.6M in 2019

Revenue up 12% to $17.4M in 2020

Stockholders’ Equity up 522% to $76.5M

ROCHESTER, N.Y., March 31, 2021 (GLOBE NEWSWIRE) — Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating business segments in direct marketing, consumer packaging, brand protection technology, healthcare, real estate, blockchain security, and securitized digital assets, today announced its financial results for its fiscal year ended December 31, 2020.

“I am pleased to report we made tremendous progress in 2020 toward our goal of transforming DSS, an initiative we first embarked upon in 2019,” stated Frank D. Heuszel, CEO of DSS. “Despite an extremely challenging business environment from COVID-19, our team executed on multiple fronts, generating a $5.7 million increase in net income from continuing operations, 12% revenue growth, and a 522% surge in stockholders’ equity. We continue to build on the successes of 2020 with several key strategic initiatives already achieved this year which I believe will help to further accelerate revenue and profit growth in the quarters ahead.”

“Because of our strong and balanced corporate performance in 2020, we are well positioned to drive sustainable growth in 2021,” continued Heuszel. “2020 was our highest net income in years. The investments made in 2020, as well as those we have made and will continue to make in 2021, place us in an advantageous position to capitalize on the wealth of opportunities across the markets we target with our diverse business segments.”

2020 Financial Highlights:

The following summarizes financial highlights of fiscal 2020:

• Net income from continuing operations increased to $3.1 million, or $1.01 per share, up $5.7 million from a net loss from continuing operations of approximately $2.6 million ($3.05 per share) in 2019. The increase in net income in 2020 primarily reflects the company’s unrealized gains of $10.6 million on its marketable securities.
• Strengthened cash position with addition of $20.2 million from multiple offerings in 2020, followed by two additional offerings in 2021 generating $61.0 million.
• Stockholders’ equity increased 522% to $76.5 million as of December 31, 2020, up from $12.3 million at December 31, 2019.
• Revenue increased 12% to $17.4 million in 2020, up from $15.6 million in 2019.
• Printed products segment revenue was $13.0 million in 2020, compared to $13.2 million in 2019.
• Technology sales, services, and licensing segment revenue was $2.1 million in 2020, compared to $2.1 million in 2019.
• Direct marketing revenue increased to $2.3 million in 2020, up from $0.2 million in 2019.

• Costs and expenses totaled $28.1 million in 2020, as compared to $18.2 million in 2019, driven by increases in sales, marketing, general, and administrative expenses, along with an increase in professional fees primarily driven by acquisition activities and consulting fees incurred by the Direct Marketing business segment.

“Since the spring of 2019, we have reduced the Company’s monthly cash burn by eliminating non-essential layers of management and redundant operating expenses, as well as by renegotiating vendor contracts and supply chain optimization,” commented Jason Grady, Chief Operating Officer of DSS. “We remain relentlessly focused on strengthening DSS by exiting unprofitable business lines, investing in and continuing to revive our core businesses, improving top line revenues and net margins, controlling costs and creating new long-term scalable, recurring revenue streams. I am very pleased with the progress our team has made on these fronts and confident that shareholders will continue to see improvements as we execute on our robust, multi-faceted, global business strategy.”

Key Highlights and Strategic Milestones:

• Completed acquisition of Impact BioMedical.
• Launched collaborative partnership with Coinstreet Partners and GSX Group to develop new digital asset exchange business in US.
• Expanded DSS Securities ecosystem through investments in WestPark Capital and BMI Capital in February 2021.
• Published results from Impact BioMedical’s in-vitro testing of Equivir and Linebacker against COVID-19, demonstrating success as a treatment, as well as a prophylactic protecting the cells from infection by the virus. Impact BioMedical also demonstrated 10-fold reduction in viral population of COVID-19 in surface disinfectant efficacy testing of its proprietary 3F Biofragrance.
• Impact BioMedical initiated bioplastics research collaboration with one of the world’s largest plastics manufacturers to develop five new types of advanced microbial-resistant plastics.
• Impact BioMedical expanded its nutraceutical product lines through investment in nano nutraceutical contract manufacturer Nano9.
• Signed global personal protective equipment (PPE) exporter as an early adopter of the Company’s new AuthentiGuard as a Service (AGaaS) anti-counterfeiting technology.
• Launched AGaaS app on The App Store.
• Premier Packaging subsidiary signed multi-year contract valued at $3.2 million per annum with one of world’s largest photography and image sharing companies; total contract valued at nearly $10 million.
• Premier Packaging subsidiary signed multi-year contract valued at $2.6 million per annum with the world leading digital retailer and manufacturing platform for photography and
  personalized products.
• Expanded board to eight members and appointed Tung Moe Chan, Group Chief Development Officer of Singapore Exchange-listed Alset International Limited, as a new director.
• Increased ownership in Sharing Services Global Corp. (OTCQB: SHRG) to 62,457,378 class A common shares, representing 32.2% ownership, as of December 31, 2020; entered into a letter of intent to provide a $30 million investment into SHRG through convertible promissory note in Q1 2021.
• Heng Fai Ambrose Chan, Chairman of DSS, through Global BioMedical Pte Ltd., converted 4,293 shares of its Series A Preferred Stock of DSS into 662,500 restricted shares of the Common Stock of the Company at an above-market conversion price of $6.48 per share.

A full analysis of results for the fiscal year ended December 31, 2020 is available in the Company’s Form 10-K filed on March 31, 2021 and is available on the Company’s website at www.dsssecure.com or through the Securities and Exchange Commission’s Edgar database at www.sec.gov.

About Document Security Systems, Inc.

DSS is a multinational company operating business segments in direct marketing, consumer packaging, brand protection technology, healthcare, real estate, blockchain security, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. Its historic business revolves around counterfeit deterrent and authentication technologies, smart packaging, and consumer product engagement. DSS is led by its Chairman and largest shareholder, Mr. Fai Chan, a highly successful global business veteran of more than 40 years specializing in corporate transformation while managing risk. He has successfully restructured more than 35 corporations with a combined value of $25 billion.

For more information on DSS visit http://www.dsssecure.com.

Investor Contact:

Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
[email protected]

Safe Harbor Disclosure

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company’s intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in the section entitled “Risk Factors” in the prospectus and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

• Dr. George Gellert MD, MPH, MPA, FABPM joins Wellteq as Chief Medical Officer

• Based in San Antonio, Texas, Dr. Gellert served most recently as Senior Medical Director at 3M Health Information Systems, Hospital Performance Improvement

• Dr. Gellert is the former Associate Enterprise and Regional Chief Medical Information Officer (CMIO) for Christus Health and held prior executive leadership roles at WebMD and GlaxoSmithKline

• Dr. Gellert was seconded as a national expert by the U.S. Department of State to advise the United Nations IAEA and its partners in the development of a global cancer control programme, developing a framework for an interagency, public-private alliance that secured funding for multidisciplinary cancer control projects in all six WHO global regions

• Dr. Gellert has domain expertise in epidemiology and health outcomes research; health informatics; population health program design, execution and evaluation; product development; business strategy/development; strategic alliances; and has authored over 150 peer reviewed articles in leading medical journals
  

VANCOUVER, British Columbia, March 31, 2021 (GLOBE NEWSWIRE) — Wellteq Digital Health Inc. (CSE: WTEQ), (the “Company” or “Wellteq”), is pleased to announce the appointment of Dr. George Gellert MD, MPH, MPA, FABPM, as Chief Medical Officer of Wellteq. Dr. Gellert has accumulated extensive experience in senior officer positions including his tenure as:

• Chief Medical Information Officer at CHRISTUS Health, an integrated delivery network including 49 hospitals and long-term care facilities and 250 clinics, where he led the successful Electronic Health Records adoption by over 15,000 physicians and 8,000 nurses in 6 US states, Mexico, Chile, and Columbia.
• Chief Medical Officer and Executive Vice President for HCORP Inc., deploying patient-centric interactive communication technologies for patient education/engagement and improvement of clinical staff efficiencies;
• Senior Vice President of Strategic Alliances at WebMD where he developed a Public-Private partnership with the UN Secretary General’s Office to create a public health Internet information portal now operated by the World Health Organisation (WHO);
• Head of Product Development and Outcomes Research at SmithKline Beecham Healthcare where he managed one of the largest multi-site health outcomes research teams in the pharmaceutical industry.

Dr. Gellert joins Wellteq to build out the Company’s “Continuum of Care” model, and to expand its corporate wellness propositions into supporting a wider range of users’ clinical, disease prevention and wellness needs. Dr. Gellert stated, “Given its track record, existing and emerging capabilities, Wellteq is ideally positioned to offer a powerful and unprecedented suite of highly integrated health promotion/wellness, disease prevention and telemedical/remote patient monitoring and virtual services that engage individuals seamlessly across their entire health care lifecycle.”

Scott Montgomery, Wellteq CEO stated, “Dr. Gellert exemplifies the hybrid of medical and commercial excellence having managed entire hospital groups in the world’s largest healthcare system while taking a senior role in advising US State and Federal Government, United Nations and WHO health initiatives. Dr. Gellert will innovate the clinical design within our virtual care platform and bring forward Wellteq’s clinical applications to help support healthcare’s effort to reduce behaviour-related illness. Today is an incredibly exciting day for Wellteq and healthcare innovation more broadly as we take another key step in shifting healthcare towards data-driven and proactive delivery in line with modern technology capabilities.”

About Wellteq Digital Health Inc.

Wellteq Digital Health Inc. is a leading provider of corporate wellness solutions developed to provide data-driven personalized health and wellness coaching to engage its users in healthier behaviours. As an enterprise (business-to-business) model Wellteq currently has two main sectors of customers, employers and insurance companies. Wellteq have secured a large multinational portfolio of customers, including UBS, DBS and Bupa Insurance, and reseller partners like Willis Towers Watson, Advanced Human Imaging and Garmin. Wellteq is developing its newly acquired Internet of Medical Things (IoMT) technologies for connected patient applications in healthcare which will extend the Wellteq’s continuum of care from preventative wellness through to virtual healthcare.

Investor Contact:

Glen Akselrod
Bristol Investor Relations
[email protected]
T: (905) 326-1888 ext 1

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Wellteq, and includes statements about, among other things, future developments and the future operations, strengths and strategies of Wellteq. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management’s assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management’s experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Wellteq’s products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Wellteq undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The CSE has neither approved nor disapproved the contents of this news release.